ORGO Q1 2024 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$355M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$110M+2.2% YoY

Gross Profit

$81M73.9% margin

Operating Income

-$4M-3.5% margin

Net Income

-$2M-1.9% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+10.4%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$458M

Total Liabilities

$180M

Stockholders' Equity

$278M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$110M	$108M	+2.2%
Gross Profit	$81M	$81M	+0.3%
Operating Income	-$4M	-$4M	+3.7%
Net Income	-$2M	-$3M	+29.3%

Revenue Segments

Advanced Wound care

$104M94%

Surgical and Sports Medicine

$6M6%